Structural comparisons of class I phosphoinositide 3-kinases.
about
Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexesGain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functionsA frequent kinase domain mutation that changes the interaction between PI3K and the membranePIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesSomatic mutations in PI3Kalpha: structural basis for enzyme activation and drug designDiscovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alphaPhosphatidylinositol 3-kinase: the oncoprotein.A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiencyA novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myelomaAkt inhibitors in clinical development for the treatment of cancer.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerActivating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome.The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFRThe favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.LncRNA AK023948 is a positive regulator of AKT.P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP.Inhibitors of phosphatidylinositol-3-kinase in cancer therapyStructural effects of oncogenic PI3Kα mutations.Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.Crossroads of PI3K and Rac pathways.Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinaseDomain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
P2860
Q24297874-8F40AD8B-CECA-47EE-86AF-9D1C7441CD95Q24339544-C57DFF53-46AC-4678-A1BF-47407DB56AB3Q27657679-F1540216-A412-4B83-B8D8-1F21A58BC343Q28247338-6A5BE59C-2D3B-4D2F-BC73-EEF54F3622E6Q28397537-FD36DD73-8EB0-4414-A620-FB134912BBE3Q33653223-E1DE32C6-9EE3-45EB-810C-12FB69220586Q33852403-3E40F13C-4A3B-4DE9-9A3C-9ED598FEFF98Q33871417-DC72F6C7-D0A9-4720-B74F-E8C7EB2789DAQ34100548-21A8F46C-2245-4043-A748-997FFF38EF33Q34203861-FA3F6CFA-844D-481B-BD52-DA563D2B5A40Q34358850-C4E3F971-67D3-4030-B46E-3B02ED706139Q34380652-43626F45-C282-4514-BD2D-0AF4C7959C81Q35238420-63D4777E-4CAF-4195-BD2C-47185661FDA1Q35628576-669FD15B-53BC-4F1C-B791-D3CED800DA38Q36064908-E48BB354-DB92-432D-8DE9-FF676C76A7E1Q36271077-0D789533-DDDD-4CFD-B290-224C542FA6E7Q37017948-7699CAB8-111B-459E-8FBB-2F0AD2ACDBFEQ37183710-2EA79082-6ACA-4ED6-85BE-FDC00AE69443Q37367106-C692CCD3-134B-4F5D-98C7-B93E39829A49Q37642607-17A7333E-AD2F-4274-8A17-7C1AC563A422Q37680192-29E88957-E135-4095-9091-6D4C8115DCFDQ37696628-15E35D1E-BE4B-49E7-941C-0B7521770B1FQ37769164-B4E9F380-B494-45DB-B27A-ED17EECCF06FQ37805091-5E1A1E19-C878-4AA5-B26E-DE27BAB9B4ACQ38459968-9165ACBE-484B-4859-B512-2DBC985C6DE5Q39766760-6EAFDF91-675F-4BDD-8DC6-3F8D74F7BAB7Q40653471-AA5229EE-D205-456C-B6B4-49FD49C1E8DFQ41348786-2B6F2AD7-6CEC-465B-8C07-72E47D441ABCQ43970436-3FE76D85-A01C-4235-8F8E-0DA816F736CDQ54442312-D5228BF0-34F7-441E-8CF5-6D47E702729F
P2860
Structural comparisons of class I phosphoinositide 3-kinases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structural comparisons of class I phosphoinositide 3-kinases.
@en
Structural comparisons of class I phosphoinositide 3-kinases.
@nl
type
label
Structural comparisons of class I phosphoinositide 3-kinases.
@en
Structural comparisons of class I phosphoinositide 3-kinases.
@nl
prefLabel
Structural comparisons of class I phosphoinositide 3-kinases.
@en
Structural comparisons of class I phosphoinositide 3-kinases.
@nl
P2860
P50
P356
P1476
Structural comparisons of class I phosphoinositide 3-kinases.
@en
P2093
Christoph Lengauer
Diana Mandelker
P2860
P2888
P304
P356
10.1038/NRC2443
P407
P577
2008-09-01T00:00:00Z